SCHEMBL23587117

SCHEMBL23587117

CC(=O)c1nc(C(F)(F)F)n2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.42
SSTR4 P31391 1/20 0.41
KMT2A Q03164 1/20 0.41
BAZ2B Q9UIF8 5/20 0.40
BAZ2A Q9UIF9 5/20 0.40
BRD4 O60885 2/20 0.40
BRD2 P25440 1/20 0.40
BRD3 Q15059 1/20 0.40
ROCK2 O75116 2/20 0.39
CNR2 P34972 1/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7499354 0.86 PTGS1 (0.45) CYP1A2SSTR4ROCK2CYP2C9CYP2D6
SCHEMBL23587331 0.85 ROCK2 (0.45) CYP1A2SSTR4ROCK2CYP2C9CYP2D6
SCHEMBL19127956 0.84 KDM4E (0.53) CYP1A2SSTR4KMT2AROCK2CNR2
SCHEMBL3897812 0.81 KMT2A (0.49) SSTR4KMT2ABAZ2BBAZ2ABRD4
SCHEMBL4319097 0.78 CNR2 (0.61) SSTR4KMT2AROCK2CNR2CYP2D6
SCHEMBL4319099 0.78 CNR2 (0.61) SSTR4KMT2AROCK2CNR2CYP2D6
SCHEMBL20674150 0.78 BAZ2B (0.46) KMT2ABAZ2BBAZ2ABRD4BRD2
SCHEMBL19150413 0.77 ROCK2 (0.41) CYP1A2KMT2AROCK2KDM4EALDH1A1
SCHEMBL15596018 0.76 KMT2A (0.44) KMT2ABAZ2BBAZ2ABRD4BRD2
SCHEMBL23937869 0.76 PTPN1 (0.51) SSTR4KMT2AHSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673886-B2 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-13 US disclosed
EP-3954681-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2022-02-16 EP disclosed
EP-3402790-B1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2021-10-06 EP disclosed
EP-3652168-B1 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2021-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673886-B2 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK MYLK, ROCK1, ROCK2 CYP1A2 2228/4885SSTR4 1660/4885KMT2A 1628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.